Researchers are studying fungi as a possible cause of strange retinopathies such as AZOOR. There are several retinopathies of unknown cause; among them AZOOR, Multifocal choroiditis, Serpiginous ...
MALVERN, Pa., April 27, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and ...
We welcome, and read with interest, the systematic review of Purtscher retinopathies by Miguel et al, 1 who described the systemic aetiologies underlying Purtscher’s, the clinical features, the ...
“In 2019 in eLife we reported the development of an advanced protein-engineering technology platform that can be used to activate the Wnt/β-catenin signaling pathway precisely and on demand. Norrin ...
In light of the elucidation of the molecular pathogenesis of some dominantly inherited retinal degenerations over the past two decades, it is timely to explore possible means of therapeutic ...
Ocugen, Inc. announced that the U.S. FDA has granted Rare Pediatric Disease Designation to its treatment OCU410ST for ABCA4-associated retinopathies, including Stargardt disease. This follows prior ...
Ocugen Inc.’s OCU-410ST (AAV5-hRORA) has been awarded orphan drug designation by the FDA for the treatment of ABCA4-associated retinopathies, including Stargardt disease, retinitis pigmentosa 19 (RP19 ...
Intergalactic Therapeutics Inc. has announced promising preclinical data with IG-002, its lead program addressing all forms of ABCA4-related retinopathies. Intergalactic’s nonviral gene therapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results